Ryoncil Revenue Growth Highlighted in AGM Trading Update
Filed with ASX · · 2 pages · English
In the deck
Story so far
Earlier from Mesoblast
- CEO Presentation to 2025 Annual General Meeting
- Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
- Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
- James M. O’Brien Appointed Chief Financial Officer at Mesoblast
- Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
Later from Mesoblast
- Mesoblast Participation at Piper Sandler Conference
- Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
- Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
- Mesoblast Enters into Non-Dilutive Lower Cost 5-Year Credit
- Mesoblast Announces Changes to Board of Directors' Leadership Roles
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast